Monitor for signs of hypoglycemia. A patient with type 2 DM who uses insulin as part of the treatment plan is at increased risk for hypoglycemia. Manifestations of hypoglycemia may vary among individuals but are consistent in the same individual. The signs are the result of both increased adrenergic activity and decreased glucose delivery to the brain, therefore, the patient may experienced tachycardia, diaphoresis, dizziness, headache, fatigue, and visual changes.